ABCL
AbCellera Biologics Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +9.1% ·
share flow +10.9% ·
net new positions +8.3%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 54 | +1 | 68.34M | $533.95M | +7 | −7 |
| Q1 2026 | 54 | -3 | 75.99M | $265.38M | +4 | −8 |
| Q4 2025 | 57 | -1 | 59.76M | $204.38M | +2 | −2 |
| Q3 2025 | 15 | +1 | 44.56M | $224.16M | +1 | −1 |
| Q2 2025 | 12 | +1 | 42.81M | $146.85M | +1 | — |
| Q1 2025 | 10 | +1 | 34.92M | $77.87M | +1 | — |
| Q4 2024 | 9 | 0 | 29.72M | $87.07M | +1 | −1 |
| Q3 2024 | 8 | -1 | 22.08M | $57.42M | — | −1 |
| Q2 2024 | 9 | — | 34.65M | $102.56M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Capital World Investors ✦ | 13.36M | 0.0% | $45.83M | 0.0% | Held | 3 | SEC ↗ |
| 2 | Baillie Gifford ✦ | 10.36M | -7.5% | $35.53M | 0.0% | ▼ Trim | 5 | SEC ↗ ×4 |
| 3 | Two Sigma Investments ✦ | 4.11M | +31.5% | $14.10M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 4 | BlackRock ✦ (passive) | 3.68M | — | $12.63M | 0.0% | n/c | 1 | SEC ↗ ×9 |
| 5 | Millennium Management ✦ | 3.40M | +290.7% | $11.65M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 6 | Renaissance Technologies ✦ | 3.31M | +14.3% | $11.34M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 2.89M | +59.3% | $9.91M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 8 | Norges Bank ✦ (passive) | 630.94K | 0.0% | $2.16M | 0.0% | Held | 5 | SEC ↗ |
| 9 | State Street Global Advisors ✦ (passive) | 614.29K | -2.0% | $2.11M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 10 | Geode Capital Management ✦ (passive) | 363.19K | +3.5% | $1.25M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 51.07K | New | $175,184 | 0.0% | New | 1 | SEC ↗ |
| 12 | Marshall Wace ✦ | 47.48K | 0.0% | $162,856 | 0.0% | Held | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| D. E. Shaw & Co. | $175,184 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 136 holders, 124.20M shares, $428.91M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director · 53.61K sh @ 10.64 · $570,442
Director · 10.00K sh @ 11.03 · $110,300
Officer · Chief Financial… · 37.20K sh @ 10.32 · $383,904
Director · 46.39K sh @ 10.37 · $481,033
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology